---
title: Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders
nct_id: NCT01104805
overall_status: COMPLETED
phase: NA
sponsor: New York State Psychiatric Institute
study_type: INTERVENTIONAL
primary_condition: Substance Abuse
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01104805.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01104805"
ct_last_update_post_date: 2017-07-11
last_seen_at: "2026-05-12T06:21:55.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders

**Official Title:** NIDA-CTN-0044: Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders Using the Therapeutic Education System (TES)

**NCT ID:** [NCT01104805](https://clinicaltrials.gov/study/NCT01104805)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 507
- **Lead Sponsor:** New York State Psychiatric Institute
- **Collaborators:** National Institute on Drug Abuse (NIDA)
- **Conditions:** Substance Abuse
- **Start Date:** 2010-04
- **Completion Date:** 2012-09
- **CT.gov Last Update:** 2017-07-11

## Brief Summary

The main objective of this study is to evaluate the effectiveness of including an interactive, web-based version of the Community Reinforcement Approach (CRA), called the Therapeutic Education System (TES), as part of community-based, outpatient substance abuse treatment.

## Detailed Description

The principal objective of the planned trial is to evaluate the effectiveness of including an interactive, web-based version of the Community Reinforcement Approach (CRA), called the Therapeutic Education System (TES), as part of community-based, outpatient substance abuse treatment. CRA is a cognitive-behavioral intervention which seeks to give patients skills to achieve and maintain abstinence and improve social functioning and is often paired with contingency management, where patients earn rewards contingent upon drug negative urines. CRA is an intensive treatment, generally delivered in individual sessions 2 to 3 times per week. Thus, it is expensive and time-consuming to deliver, to train clinical staff, and to provide supervision to maintain clinical staff skill. However, because CRA is oriented toward knowledge and skills, it lends itself to being delivered by computer, using computer-interactive learning technologies.

Individuals accepted into community-based outpatient treatment for substance use disorders (excluding those receiving opioid pharmacotherapy for opioid dependence) will be eligible to participate. This is a multi-site, controlled trial, using NIDA's Clinical Trials Network platform, at approximately 10 Community Treatment Programs, in which participants (N = approximately 500) will be randomized to receive 12 weeks of either: (1) Treatment-as-Usual (TAU), reflecting standard treatment at the collaborating treatment programs in which participants are enrolled, or (2) a modification of TAU which includes access to the TES. It is hypothesized that access to TES will improve substance use outcome and retention in outpatient treatment.

Computer interactive interventions like TES have the potential to deliver science-based psychosocial treatments with high fidelity and cost-effectiveness while conserving clinician time to focus on monitoring and addressing patients' needs. If found to be effective, TES could substantially advance the substance abuse treatment system by improving quality of care delivered, increasing availability of treatment slots by extending and leveraging the efforts of clinical staff, and projecting treatment to rural and other underserved areas.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Male and female patients, 18 years or older, accepted for outpatient, substance abuse treatment at a participating study site.
* Self-report any substance use problem (including alcohol, as long as they also report other drug use in addition to alcohol).
* Self-report recent drug use.
* Within 30 days of initiating treatment at a collaborating study site.
* Self-report a planned substance abuse treatment episode of at least 3 months.

Exclusion Criteria:

* Receiving opioid replacement medication.
* Plan to move out of the area within the next 3 months.
* Insufficient ability to provide informed consent.
* Insufficient ability to use English to participate meaningfully in the consent process, the interventions or research assessments.
```

## Arms

- **Therapeutic Education System (TES)** (EXPERIMENTAL) — Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
- **Treatment-as-Usual (TAU)** (OTHER) — Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.

## Interventions

- **Therapeutic Education System (TES)** (BEHAVIORAL) — Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
- **Treatment-as-Usual (TAU)** (BEHAVIORAL) — Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.

## Primary Outcomes

- **Reduced Substance Use and Improved Treatment Retention** _(time frame: 12-week Treatment Phase)_ — Compared to patients assigned to Treatment as Usual (TAU), patients assigned to modified TAU plus the Therapeutic Education System (Modified TAU + TES) will have:

1. reduced substance use (measured by a combination of self-report confirmed by urine toxicology) and
2. better retention in treatment at their community-based treatment programs.

## Secondary Outcomes

- **Effectiveness** _(time frame: 12-week treatment phase, 3- and 6-months post treatment)_
- **Sustained outcome** _(time frame: 3- and 6-months post treatment)_
- **Economic Analysis** _(time frame: 12-week treatment phase, 3- and 6-months post treatment)_
- **Coping Skills** _(time frame: 12-week treatment phase, 3- and 6-months post treatment)_

## Locations (10)

- MCCA: Midwestern CT Council on Alcoholism, Danbury, Connecticut, United States
- The Center for Drug Free Living, Orlando, Florida, United States
- Hina Mauka, Waipahu, Hawaii, United States
- Midtown Community Mental Health Center, Indianapolis, Indiana, United States
- HARBEL Prevention and Recovery Center, Baltimore, Maryland, United States
- Stanley Street Treatment and Resources (SSTAR), Fall River, Massachusetts, United States
- Project Outreach, West Hempstead, New York, United States
- Willamette Family, Inc., Eugene, Oregon, United States
- Homeward Bound, Dallas, Texas, United States
- Evergreen Manor, Everett, Washington, United States

## Recent Field Changes (last 30 days)

- `locations.project outreach|west hempstead|new york|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `locations.willamette family, inc.|eugene|oregon|united states` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mcca: midwestern ct council on alcoholism|danbury|connecticut|united states` — added _(2026-05-12)_
- `locations.the center for drug free living|orlando|florida|united states` — added _(2026-05-12)_
- `locations.hina mauka|waipahu|hawaii|united states` — added _(2026-05-12)_
- `locations.midtown community mental health center|indianapolis|indiana|united states` — added _(2026-05-12)_
- `locations.harbel prevention and recovery center|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.stanley street treatment and resources (sstar)|fall river|massachusetts|united states` — added _(2026-05-12)_
- `locations.homeward bound|dallas|texas|united states` — added _(2026-05-12)_
- `locations.evergreen manor|everett|washington|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01104805.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01104805*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*